Introduction

While xenograft models remain the gold standard for studying human tumor biology in vivo, the demand for more rapid, cost-effective, and human-relevant systems has accelerated the development of next-generation alternatives. Among these, tumor organoids, organoid-on-a-chip systems, and ex vivo tumor explants represent complementary technologies that can capture patient-specific features while overcoming some limitations of xenografts. These platforms are increasingly integrated into preclinical pipelines, often in combination with xenografts, to create robust translational workflows.

Tumor Organoids

Organoids are three-dimensional structures derived from patient tumor samples or stem cells that self-organize into miniature versions of tumors in vitro. They preserve the genetic, histological, and functional heterogeneity of the source tissue, making them highly predictive of patient drug responses.

• Advantages: Rapid establishment (within weeks), scalability for high-throughput screening, and ability to model tumor heterogeneity.
• Applications: Testing targeted therapies, chemotherapy regimens, and personalized treatment options. Organoids can also be transplanted into immunodeficient mice to create organoid-derived xenografts (ODX), bridging in vitro and in vivo research.
• Limitations: Organoids often lack a fully functional tumor microenvironment and immune system, requiring co-culture systems or subsequent xenografting for complete modeling.

Organoid-on-a-Chip

Microfluidic “organ-on-a-chip” platforms integrate tumor organoids with engineered microenvironments, enabling dynamic control of fluid flow, nutrient gradients, and drug delivery. These systems replicate key physiological conditions such as shear stress and oxygen gradients, which strongly influence drug response.

• Advantages: Enhanced physiological relevance, real-time imaging, and the ability to mimic organ-specific tumor niches (e.g., liver, brain).
• Applications: Drug penetration studies, immune–tumor interaction modeling, and evaluation of metastasis mechanisms within controlled environments.
• Limitations: Technical complexity, standardization challenges, and the need for specialized equipment.

Ex Vivo Tumor Explants

Ex vivo tumor explant systems involve culturing intact tumor fragments from patients or xenografts under optimized conditions that preserve native architecture, stromal components, and immune infiltrates.

• Advantages: Retention of full microenvironment complexity, including vasculature and extracellular matrix.
• Applications: Short-term drug screening, biomarker discovery, and validation of therapeutic combinations. Explant models provide direct insight into how a patient’s tumor might respond to therapy before clinical administration.
• Limitations: Limited lifespan (days to weeks) and scalability constraints.

Comparative Advantages Over Xenografts

• Speed: Organoids and explants can be established and screened more quickly than xenografts, making them ideal for real-time clinical decision-making.
• Scalability: Organoids and organoid-on-a-chip platforms allow high-throughput drug testing, which is impractical in animal models.
• Complementarity: Xenografts remain superior for studying systemic interactions, metastasis, and pharmacokinetics, but integration with organoid-based systems enhances predictive accuracy.

Future Perspectives

The convergence of xenografts with next-generation alternatives is shaping a hybrid preclinical ecosystem. Future research will likely employ multi-platform pipelines, where patient tumors are used to generate organoids for rapid screening, organoid-on-a-chip for microenvironmental modeling, and xenografts for systemic validation. Advances in 3D bioprinting, immune cell co-culture, and single-cell analytics will further refine these platforms. Collectively, these approaches will expand the predictive power of preclinical oncology, accelerating the development of personalized therapeutic strategies.